Patents by Inventor R. Scott Thies

R. Scott Thies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10351821
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 16, 2019
    Assignee: Asterias Biotherapeutics Inc.
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Publication number: 20190024053
    Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.
    Type: Application
    Filed: January 22, 2018
    Publication date: January 24, 2019
    Inventor: R. Scott Thies
  • Publication number: 20180291337
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Application
    Filed: October 16, 2017
    Publication date: October 11, 2018
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Patent number: 9790466
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 17, 2017
    Assignee: Asterias Biotherapeutics, Inc.
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Publication number: 20140134721
    Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.
    Type: Application
    Filed: August 30, 2013
    Publication date: May 15, 2014
    Applicant: Asterias Biotherapeutics, Inc.
    Inventor: R. Scott Thies
  • Publication number: 20130274215
    Abstract: The present invention provides methods for the prevention, treatment and/or amelioration of fibrosis or fibrotic conditions. The present invention further provides small molecule inhibitors of Wnt- and TGF-p-mediated ?-catenin signaling to prevent, treat and/or ameliorate fibrosis or fibrotic conditions. Kits comprising small molecule inhibitors of Wnt- and TGF-p-mediated ?-catenin signaling and methods of identifying small molecule inhibitors of Wnt- and TGF-p-mediated ?-catenin signaling are also provided.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 17, 2013
    Applicant: FATE THERAPEUTICS, INC.
    Inventors: R. Scott Thies, Francine S. Farouz, David Jenkins
  • Patent number: 8546101
    Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: October 1, 2013
    Assignee: Geron Corporation
    Inventor: R. Scott Thies
  • Publication number: 20120322146
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Application
    Filed: July 30, 2012
    Publication date: December 20, 2012
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Patent number: 8252586
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: August 28, 2012
    Assignee: Geron Corporation
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Publication number: 20120207744
    Abstract: The present invention provides compositions and methods of using the compositions to alter the developmental potency of a cell. The present invention provides in vivo and ex vivo cell reprogramming and programming methods suitable for autologous cell therapy and regenerative medicine.
    Type: Application
    Filed: March 19, 2010
    Publication date: August 16, 2012
    Inventors: John D. Mendlein, Francine S. Farouz, R. Scott Thies, Daniel Shoemaker
  • Publication number: 20120202288
    Abstract: Provided are improved pharmaceutical compositions that comprise ligands or agonists to prostaglandin EP receptors, and/or cyclic AMP enhancers, and suitable organic solvents that are substantially free of methyl acetate, the compositions being provided for storage and/or use in an endotoxin-free vessel, such as a tube or PE bag. The compositions are suitable for in vitro, ex vivo, and in vivo use, and in particular for ex vivo therapeutic use, such as in hematopoietic stem cell transplants. Also provided are methods of using the compositions in ex vivo therapeutic applications, and methods of preparing the compositions. Kits with instructions on use are also provided.
    Type: Application
    Filed: March 18, 2010
    Publication date: August 9, 2012
    Applicant: FATE THERAPEUTICS, INC.
    Inventors: John D. Mendlein, Francine S. Farouz, R. Scott Thies, Daniel Shoemaker
  • Patent number: 8153428
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: April 10, 2012
    Assignee: Geron Corporation
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Publication number: 20110129867
    Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.
    Type: Application
    Filed: February 4, 2011
    Publication date: June 2, 2011
    Inventor: R. Scott Thies
  • Patent number: 7906330
    Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: March 15, 2011
    Assignee: Geron Corporation
    Inventor: R. Scott Thies
  • Patent number: 7763463
    Abstract: This disclosure provides improved methods for obtaining populations of dopaminergic neurons from pluripotent stem cells. The process involves taking a population of neural precursor cells derived from a line of human embryonic stem cells, and culturing the cells in a medium that contains a neurotrophin, either cyclic adenosine monophosphate (cAMP) or a compound that elevates intracellular cAMP levels, and optionally an antioxidant such as ascorbic acid. Cell populations have been obtained that contain a high proportion of cells staining for tyrosine hydroxylase, which is a feature of dopaminergic neurons. The neural progenitors and terminally differentiated neurons of this invention can be generated in large quantities for use in drug screening and the treatment of clinically important neurological disorders, such as Parkinson's disease.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: July 27, 2010
    Assignee: Geron Corporation
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Publication number: 20090305405
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Application
    Filed: July 10, 2009
    Publication date: December 10, 2009
    Applicant: GERON CORPORATION
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Publication number: 20090291495
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Application
    Filed: June 3, 2009
    Publication date: November 26, 2009
    Applicant: Geron Corporation
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Patent number: 7560281
    Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: July 14, 2009
    Assignee: Geron Corporation
    Inventors: Melissa K. Carpenter, R. Scott Thies
  • Patent number: 7250294
    Abstract: This invention provides populations of neural progenitor cells and differentiated neurons, obtained by culturing pluripotent cells in special growth cocktails. The technology can be used to produce progenitors that proliferate through at least ˜40 doublings, while maintaining the ability to differentiate into a variety of different neural phenotypes, including dopaminergic neurons. The neural progenitors and terminally differentiated neurons of this invention can be generated in large quantities for use in drug screening and the treatment of neurological disorders.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: July 31, 2007
    Assignee: Geron Corporation
    Inventors: Melissa K. Carpenter, Jerrod J. Denham, Margaret S. Inokuma, R. Scott Thies
  • Patent number: 7091007
    Abstract: Novel serine/threonine receptor proteins and BMP receptor proteins are disclosed, as well as DNA molecules encoding the BMP receptor proteins and methods of using the receptor proteins. Further disclosed are truncated BMP receptor proteins and molecules which act as ligands to the BMP receptor proteins.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: August 15, 2006
    Assignee: Genetics Institute, LLC
    Inventors: John M. Wozney, Anthony J. Celeste, R. Scott Thies, Noboru Yamaji